0K91 Stock Chart & Stats
€4.58
€0.08(2.23%)
At close: 4:00 PM EST
€4.58
€0.08(2.23%)
Day’s Range― - ―
52-Week Range€1.62 - €24.40
Previous CloseN/A
Volume0.00
Average Volume (3M)661.00
Market Cap
€16.76M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding6,398,605
10 Day Avg. Volume289
30 Day Avg. Volume661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Quantum Biopharma News
0K91 FAQ
What was Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price range in the past 12 months?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B lowest stock price was €1.62 and its highest was €24.40 in the past 12 months.
What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap is €16.76M.
When is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s earnings last quarter?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B released its earnings results on May 06, 2026. The company reported -€2.606 earnings per share for the quarter, missing the consensus estimate of -€0.426 by -€2.18.
Is Quantum Biopharma Ltd. Subordinate Voting Shares Class B overvalued?
According to Wall Street analysts Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price is currently Overvalued.
Does Quantum Biopharma Ltd. Subordinate Voting Shares Class B pay dividends?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B does not currently pay dividends.
What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate is -0.37.
How many shares outstanding does Quantum Biopharma Ltd. Subordinate Voting Shares Class B have?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B has 6,398,605 shares outstanding.
What happened to Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price movement after its last earnings report?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B reported an EPS of -€2.606 in its last earnings report, missing expectations of -€0.426. Following the earnings report the stock price went down -1.554%.
Which hedge fund is a major shareholder of Quantum Biopharma Ltd. Subordinate Voting Shares Class B?
Currently, no hedge funds are holding shares in DE:0K91
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quantum Biopharma Ltd. Subordinate Voting Shares Class B
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.